Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO
The South San Francisco, California-based company is seeking up to $132.6 million by offering 7.8 million shares priced between $15 and $17 each.
The IPO could be one of the several offerings from the biotech sector in the coming weeks as a clutch of pharmaceutical companies looks to test investor appetite towards the industry.
"Despite investors shying away from the sector since the election, we're still hopeful that easing monetary policy could provide a tailwind throughout the year," said IPOX research analyst Lukas Muehlbauer, adding the recent biotech IPO filings are a positive sign.
Drug developers Aardvark Therapeutics, Aurion Biotech, Sonna Therapeutics, Metsera, and Odyssey Therapeutics are among the IPO hopefuls that have filed their paperwork in recent weeks.
Maze, backed by healthcare venture firms ARCH Venture and Third Rock Ventures, as well as Alphabet's (GOOGL.O), opens new tab venture capital arm GV, raised $115 million in a funding round just over a month ago.
The company is developing drugs to treat renal, cardiovascular and metabolic diseases.
Maze's pipeline includes two lead experimental candidates for chronic kidney disease - MZE829, in a mid-stage study, and MZE782, in an early-stage study with initial data expected in the second half of 2025.
The company is also developing MZE001, an experimental therapy to treat a rare muscle disorder Pompe disease, with Japan's Shionogi (4507.T), opens new tab, after a 2023 agreement for the therapy with French drugmaker Sanofi (SASY.PA), opens new tab fell apart due to U.S. Federal Trade Commission objections.
J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities are the underwriters for the offering.
Maze will list on the Nasdaq under the symbol "MAZE".
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
4 minutes ago
- Daily Mail
Neurologist warns against popular sleep aid that could fuel your risk of dementia in later life - 'I'd never use it'
A neurologist has revealed he would never use a white noise machine to help himself sleep—because he claims it may increase your risk of dementia. In a recent video, Dr. Baibing Chen, who posts as Dr. Bing on TikTok, told his 144,500 followers that the machines have been linked to hearing loss, one of the known triggers for the devastating illness. It has become a popular trend to listen to 'white noise'—which sounds similar to a television or radio static—to aid sleep, with devotees streaming the soothing background noise from special machines or phone apps. Some sleep professionals and parenting influencers claim that the steady background noise helps the brain focus less on sudden, disruptive noises that could break concentration or wake them up. But Dr. Bing wants people to think twice before they hunker down for their next static-soundtracked good night's sleep. In a new clip, in which the Michigan-based neurologist shared three things he would never do at night, he said: 'I don't blast my white noise machine. 'Not all of you use white noise machines, but if you do, I get it. I use one. You are probably trying to block out traffic, your partner's snoring, or your dog licking his paw at 2 am in the morning. 'But if it is (set) too loud, that can actually lead to hearing damage over time. And, as I have mentioned in my previous videos, hearing loss is one of the biggest risk factors for dementia later in life.' While it's important to stress that there isn't direct evidence linking white noise machines to an increased risk of dementia later in life, there have been studies linking them to hearing loss. However, if the idea of trying to nod off without any background noise is your idea of a living nightmare, don't fret—just turn it down. Dr. Bing advised to make sure the noise is set to no louder than '50 decibels, max'. He added that if you're unable to set the volume on the device itself, you can check the volume with an Apple watch or by using a free phone app like Decibel X which 'literally takes two seconds'. According to the conclusion of a 2021 study which found that the machines are linked to hearing loss in infants, parents should ensure they are placed at least 30cm away from children, and the volume isn't set to the maximum. In 2024, researchers who reviewed 20 studies found existing data supports the need for limiting maximum volume and duration on white noise devices. And earlier this year, US scientists tracked almost 3,000 elderly adults with hearing loss and found almost a third of all dementia cases could be attributed to the issue. It is difficult to make a direct link between these studies to suggest it backs up his claim, because they looked at different age groups. However, several studies suggested a link between being exposed to noise pollution, which is unwanted or disturbing sounds, and dementia. In Dr. Bing's video, which has been watched more than 15,300 times, the second thing the he revealed he would never do is leave a night light on. He said: 'I know it feels cozy to some people and helps you get to the bathroom without stepping on a piece of Lego. 'But even a small artificial or blue light can lower melatonin, spike your blood sugar and keep your brain in a kind of awake mode all night. 'Instead try to use a motion sensing amber night light. It only turns on when you move and doesn't trick your brain into thinking its sunrise, while your just trying to use the bathroom in peace.' The final thing he said he'd never do at night is getting out of bed too quickly, which he claimed can be linked to brain bleeds. He said: 'One of the most common things I see in the hospital in the middle of the night is people coming into the ER with brain bleeds from fainting.' These patients, he explained, get them 'after getting up from bed or up from the toilet too quickly'. After posting the video, several social media users commented they simply can't go without the white noise or a nightlight.
Reuters
4 minutes ago
- Reuters
Exclusive: Google makes new proposal to stave off EU antitrust fine, document shows
BRUSSELS, July 2 (Reuters) - Google (GOOGL.O), opens new tab has proposed fresh changes to its search results in an attempt to fend off growing criticism from rivals, a week before a key meeting that could lead to yet another EU antitrust fine, according to a document seen by Reuters. The U.S. tech giant has been under pressure after being hit in March with European Union antitrust charges of unfairly favouring its own services such as Google Shopping, Google Hotels and Google Flights over competitors. The company, owned by Alphabet, will meet its rivals and the European Commission to discuss its proposals during a July 7-8 workshop in Brussels, the document said. The EU's landmark Digital Markets Act, under which Google has been charged, sets out a list of dos and don'ts for Big Tech aimed at curbing their power and giving rivals more room to compete and consumers more choice. Last week, Google offered to create a box at the top of the search page for a so-called vertical search service (VSS) which would contain links to specialised search engines as well as to hotels, airlines, restaurants and transport services. The latest offer, called Option B, is an alternative to last week's proposal, according to a Google document sent by the Commission to involved parties and seen by Reuters. "Under 'Option B', whenever a VSS box is shown, Google will also show a box that includes free links to suppliers," the document said. The box for suppliers - in essence hotels, restaurants, airlines and travel services - would be below the VSS box, with Google organising the information about the suppliers. Option B "provides suppliers opportunities while not creating a box that can be characterised as a Google VSS", the document said. "We've made hundreds of alterations to our products as part of our DMA compliance," a Google spokesperson said. "While we strive for compliance, we remain genuinely concerned about some of the real world consequences of the DMA, which are leading to worse online products and experiences for Europeans." Google risks a fine as much as 10% of its global annual revenue if found in breach of the DMA.
Reuters
5 minutes ago
- Reuters
Health Rounds: 3D printed insulin-producing cells show promise for type 1 diabetes in lab tests
July 2 (Reuters) - Insulin-producing human pancreas cells can be manufactured with 3D printers, researchers reported at the International Transplant Congress, opens new tab underway in London. Using a bio-ink made from human pancreatic tissue from which all cellular components had been removed, and alginate - a substance derived from seaweed - they printed human pancreatic islet cells. The printed cells remained alive and functional in test tubes for up to three weeks, maintaining strong insulin responses to glucose and showing real potential for future clinical use, the researchers said. While current methods of isolating islet cells for transplantation strip away the structural scaffold that supports the cells, the bio-ink retains key components of that extracellular matrix, thereby improving the cells' survival and function, the researchers said. The printed cells were more efficient than standard islet cell preparations at releasing insulin when exposed to glucose. By day 21, the bio-printed islets showed a stronger ability to sense and react to blood sugar levels, and they maintained their structure without clumping or breaking down. In traditional islet-cell transplants, done in patients with type 1 diabetes who experience dangerous and unpredictable low blood sugar episodes, islet cells from human donors are infused into the liver. The 3D-printed islets would be implanted under the skin using local anesthesia and a small incision, which could be safer and more comfortable option for patients, the researchers said. The team is now testing the bio-printed cells in animals and exploring long-term storage options that could make the therapy widely available. 'This is one of the first studies to use real human islets instead of animal cells in bio-printing, and the results are incredibly promising,' study leader Quentin Perrier of Wake Forest University School of Medicine in North Carolina said in a statement. 'It means we're getting closer to creating an off-the-shelf treatment for diabetes that could one day eliminate the need for insulin injections.' GENE EDITING BREAKTHROUGH IN CELLS' ENERGY FACTORIES Incurable disorders of mitochondria, the energy-producing 'factories' inside of cells, may one day be addressed by gene therapies, lab experiments suggest. Mitochondria – specialized structures within cells - have their own DNA, separate from the DNA in the cell's nucleus. Mutations in mitochondrial DNA can cause a variety of debilitating conditions affecting multiple organs, particularly those that require high energy, such as the brain, liver, heart, muscles, and kidneys. Existing gene editing tools like CRISPR have not been useful for these disorders because they can't efficiently pass through the mitochondrial membranes. 'Using a new kind of gene editing tool, we were able to fix DNA mistakes that cause mitochondrial disease,' said study leader Dr. Martijn Koppens from the University Medical Center Utrecht in the Netherlands. To cut and paste pieces of DNA, the new tool uses different mechanisms and components than CRISPR. For example, instead of the Cas protein, the new tool, called DdCBE, uses an inactive version of a bacterial toxin as its molecular scissors. To deliver the 'scissors' to the mitochondria, the tool uses mRNA encapsulated in tiny lipid particles, a transport method also used to deliver COVID-19 vaccines. As reported in PLoS Biology, opens new tab, Koppens' team successfully used their tool to introduce a mutation into a gene in liver cell mitochondria, thereby disrupting energy production in the cells. They were also able to correct a mutation in mitochondria from a patient with a genetic kidney disorder. 'I envision that in the near future, mitochondrial gene editing will be used to generate accurate mitochondrial disease models, which will transform basic research as well as therapy development,' Koppens said. Blood thinner therapy need not be delayed in most patients with a recent stroke attributable to an irregular heartbeat, according to a new analysis. Pooling data from four randomized trials involving nearly 5,500 patients with atrial fibrillation and a recent stroke, researchers found that starting direct oral anticoagulants - which prevent formation of blood clots - within four days was safe and effective. These drugs include Johnson & Johnson's (JNJ.N), opens new tab Xarelto or Eliquis from Bristol Myers Squibb (BMY.N), opens new tab and Pfizer (PFE.N), opens new tab. Atrial fibrillation can lead to blood clots in the heart that dislodge and travel to the brain, causing a stroke. Blood thinners can prevent clots, but they also increase the risk of bleeding in the brain, so it has been common practice to hold off for a while after a stroke before starting them. Based on the safety observed in the current analysis, 'the benefits of early initiation of blood-thinning treatment are clear," study leader Nick Freemantle of University College London said in a statement. "This approach ensures that crucial treatments are not delayed or missed, particularly for patients who are discharged from the hospital." Patients were split into two groups, with 2,691 receiving the blood thinners within 4 days and 2,750 starting the pills on day 5 or later. The incidence of either recurrent strokes from blood clots or strokes from bleeding in the brain was 2.1% with early anti-coagulation administration and 3.0% with delayed treatment, researchers reported in The Lancet, opens new tab. There was no increase in brain bleeding in the early-treatment group. However, few patients in the trial had experienced strokes that extensively damaged the brain, which would have increased the bleeding risks associated with starting the blood thinners right away. An editorial, opens new tab published with the study concludes that overall, the findings favor early initiation of oral anticoagulation in patients with strokes related to atrial fibrillation, especially those with smaller amounts of brain damage. However, the editorial noted some additional factors for providers to consider. 'Adherence to strict predefined early or late initiation thresholds might oversimplify the complexity" of deciding when to start blood thinners, it noted. It said there should be an assessment of other co-morbidities, including advanced age, other medications being taken and frailty, when delayed blood thinner therapy "might derive increased benefit.' (To receive the full newsletter in your inbox for free sign up here)
